Thanks.
I'm hoping to see some more responses and good DOR from the RP2 trial.
Yes, in Q1 2022
• Initial single agent data in all comers in the RP3 PhI.
• Initial data from RP1 plus Opdivo in anti-PD-1 failed CSCC.
• RP1 single agent initial data in CSCC organ transplant patients.
• Also, details on RP2/3 development strategy.
Then, Q4
• CERPASS (CSCC registration-directed trial) primary read out trigger.
• IGNYTE (anti-PD-1 failed melanoma registration-directed trial) read out.
• RP1 plus Opdivo in anti-PD1 failed NSCLC data.
• RP1 plus Opdivo in anti-PD1 failed CSCC updated.
• RP1 single agent data in CSCC organ transplant patients.
• RP2 liver mets cohort expansion data.
• Initial data from anti-PD-1 combination cohort with RP3.
Recent REPL News
- Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/07/2024 09:00:00 PM
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions • GlobeNewswire Inc. • 03/26/2024 11:30:00 AM
- Replimune to Present at the American Association for Cancer Research Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Replimune to Present at Three Upcoming Investor Conferences • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:21:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 01:09:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 01:05:16 PM
- Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing • PR Newswire (US) • 01/16/2024 09:06:00 AM
- DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing • PR Newswire (US) • 01/16/2024 08:59:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:37 PM
- Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/28/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 10:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 12:19:32 PM
- Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers • GlobeNewswire Inc. • 12/05/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2023 01:01:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2023 01:00:42 AM
- Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research • GlobeNewswire Inc. • 11/08/2023 02:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 10:03:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 01:15:42 PM
- Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy • GlobeNewswire Inc. • 11/03/2023 11:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 12:04:58 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 12:03:38 AM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM